

## Appendix two: tables of results from pairwise meta-analyses

Tables report pairwise posterior median odds ratios and 95% credible intervals obtained from WinBUGS analyses.  $I^2$  reported as a measure of between trial heterogeneity and the p-value for the  $\chi^2$  test for homogeneity. Reported for all four outcomes: 48-hour delay pre-term delivery, Neonatal mortality, Neonatal respiratory distress syndrome and all cause maternal side effect. Heterogeneity statistics reported for trials with  $\leq 3$  trials.

48-hour delay delivery					
Comparison		Trials	Odds ratio (95% CrI)		$I^2$ % and p-value
Active	Control				
Betamimetic	Placebo	4 trials	3.37	(0.96, 16.05)	56.1% p=0.077
PI	Placebo	2 trials	14.57	(4.30, 60.85)	Not estimated
MS	Placebo	3 trials	2.69	(0.37, 19.73)	95.4% p<0.001
ORB	Placebo	2 trials	1.51	(1.06, 2.15)	Not estimated
Nitrates	Placebo	1 trial	1.13	(0.54, 2.38)	Not estimated
PI	Betamimetic	3 trials	3.04	(0.77, 12.73)	0% p= 0.905
CCB	Betamimetic	14 trials	1.12	(0.70, 1.76)	28.2% p=0.154
MS	Betamimetic	8 trials	1.09	(0.51, 2.16)	7.7% P=0.371
ORB	Betamimetic	6 trials	0.89	(0.52, 1.53)	0% p= 0.988
CCB	PI	1 trial	79.82	(5.50, 35120)	Not estimated
MS	PI	3 trials	0.85	(0.24, 2.95)	0% p=0.397
Nitrates	CCB	1 trial	0.77	(0.13, 4.08)	Not estimated
MS	CCB	5 trials	0.88	(0.46, 1.80)	0% p=0.971
MS	Other	1 trial	1.46	(0.42, 5.38)	Not estimated

Neonatal mortality					
Comparison		Trials	Odds ratio (95% CrI)		$I^2$ % and p-value
Active	Control				
Betamimetic	Placebo	6 trials	0.39	(0.10, 1.42)	78.1% p< 0.001
PI	Placebo	3 trials	1.08	(0.14, 10.03)	0% P=0.646
MS	Placebo	3 trials	1.08	(0.15, 6.82)	51.8% P=0.125
ORB	Placebo	1 trial	4.74	(1.12, 34.19)	Not estimated
PI	Betamimetic	2 trials	1.05	(0.18, 6.22)	Not estimated
CCB	Betamimetic	8 trials	0.56	(0.13, 2.00)	0% p=0.934
Others	Betamimetic	2 trials	3.63	(1.15, 14.11)	Not estimated
MS	Betamimetic	3 trials	1.16	(0.18, 6.44)	0% p=0.659
ORB	Betamimetic	5 trials	0.62	(0.17, 1.92)	0% p=0.669
CCB	PI	1 trial	0.05	(0.00, 1.02)	Not estimated
MS	PI	3 trials	3.16	(0.35, 43.64)	0% p= 0.417
MS	CCB	2 trials	0.4	(0.01, 5.26)	Not estimated
ORB	CCB	1 trial	1.16	(0.29, 4.79)	Not estimated

Respiratory distress syndrome					
Comparison		Trials	Odds ratio (95% CrI)		I <sup>2</sup> % and p-value
Active	Control				
Betamimetic	Placebo	6 trials	0.62	(0.28, 1.02)	0% p=0.495
PI	Placebo	3 trials	0.99	(0.16, 5.68)	30% p=0.240
MS	Placebo	2 trials	1.04	(0.52, 2.07)	Not estimated
ORB	Placebo	2 trials	1.36	(0.92, 2.04)	Not estimated
PI	Betamimetic	2 trials	0.79	(0.32, 1.87)	Not estimated
CCB	Betamimetic	7 trials	0.65	(0.32, 1.42)	0% p=0.886
Others	Betamimetic	1 trial	2.84	(1.06, 8.49)	Not estimated
MS	Betamimetic	2 trials	1.78	(0.55, 6.18)	Not estimated
ORB	Betamimetic	5 trials	0.90	(0.34, 3.14)	6.3% p=0.371
MS	PI	4 trials	1.01	(0.40, 2.72)	0% p=0.790
MS	CCB	2 trials	1.18	(0.66, 2.15)	Not estimated
ORB	CCB	2 trials	0.84	(0.41, 1.70)	Not estimated
MS	Other	1 trial	0.99	(0.35, 2.79)	Not estimated

Maternal side effects (all cause)					
Comparison		Trials	Odds ratio (95% CrI)		I <sup>2</sup> % and p-value
Active	Control				
Betamimetic	Placebo	4 trials	12.26	(3.66, 61.03)	37.8% p=0.186
PI	Placebo	2 trials	2.31	(0.62, 9.60)	Not estimated
CCB	Placebo	1 trial	2.91E+08	(389.2, 1.40E+26)	Not estimated
MS	Placebo	1 trial	8.2	(1.30E+6, 1.73e+17)	Not estimated
ORB	Placebo	2 trials	2.08	(1.24, 3.55)	Not estimated
Nitrates	Placebo	1 trial	2.27	(1.18, 4.43)	Not estimated
PI	Betamimetic	4 trials	0.05	(0.01, 0.19)	20.3% p=0.288
CCB	Betamimetic	15 trials	0.14	(0.05, 0.36)	81.1% p<0.001
MS	Betamimetic	6 trial	0.45	(0.11, 1.17)	87.0% p<0.001
ORB	Betamimetic	6 trials	0.05	(0.03, 0.14)	51.4% p=0.067
CCB	PI	1 trial	2.25	(0.90, 5.95)	Not estimated
MS	PI	3 trials	3.02	(0.44, 27.95)	88.3% p<0.001
Nitrates	CCB	1 trial	2.08	(0.59, 8.19)	Not estimated
MS	CCB	5 trials	1.79	(0.52, 5.57)	71.7% p=0.007
ORB	CCB	2 trials	0.91	(0.45, 1.84)	Not estimated
Nitrates	MS	1 trial	8.12	(0.92, 243.2)	Not estimated